Back to search
FDAFDA · Food and drugs·Recall number D-0012-2027

Biospectra Tris/Tromethamine, USP, GMP, API Grade, Manufactured at 100 Majestic Way, Bangor, PA 18013, NDC 64173-101-25

Published October 14, 2026 · Recall initiated: July 29, 2026

Summary

FDA records drug Class II recall D-0012-2027, published October 14, 2026 and initiated July 29, 2026. Recalling firm: BioSpectra, Inc.; Status: Ongoing; Reported quantity: 200 kg; Lot: Lot#: TRIS -E04-0226-0016; Exp 2/29/28. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed stability specifications

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
BioSpectra, Inc.
Distributor
CA
Lot
Lot#: TRIS -E04-0226-0016; Exp 2/29/28
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Biospectra Tris/Tromethamine, USP, GMP, API Grade, Manufactured at 100 Majestic Way, Bangor, PA 18013, NDC 64173-101-25 recalled?

Yes. FDA published recall D-0012-2027 on October 14, 2026. Reported hazard: Failed stability specifications

What should I do if I have this product?

Voluntary: Firm initiated · Telephone